Allergy Therapeutics is a market leader in pioneering immunology technologies, specialising in the research and development of allergy treatments. The organisation has R&D and production facilities across Europe, including both the UK and Spain.
Allergy Therapeutics decided to update its existing EAM solution, IBM Maximo, to a new cloud-based version. The goal of this project was to streamline its multi-site Enterprise Asset Management operations, as well as its compliance, regulatory and safety procedures – starting initially at its UK and Spanish plants.
Peacock Engineering was brought in by Allergy Therapeutics to carry out its move to cloud and EAM system upgrade, to help them unlock all the benefits that a new system could offer.
Ensuring regulatory compliance with 21 CFR Part 11
Peacock Engineering implemented a new version of Maximo that enables Allergy Therapeutics to use one IBM Maximo installation, with a multiple site structure.
Being in a heavily regulated industry (Pharmaceuticals), Allergy Therapeutics needed to comply with 21 CFR Part 11, which governs electronic records and signatures throughout all work processes. Allergy Therapeutics have been using IBM Maximo to support their manufacturing facilities for more than a decade. The system is validated for CFR21 Part 11, and Peacock has worked with Allergy Therapeutics to upgrade the system multiple times.
Peacock Engineering was once again trusted by Allergy Therapeutics to help review and update their existing system validation documentation, to ensure it was in-line with the new version being deployed. This in turn made the joint validation process simpler and more efficient.
Optimising enterprise asset management and compliance for Allergy Therapeutics
Allergy Therapeutics benefits from our secure ISO27001 certified service, with all day-to-day information security responsibility managed by us.
The agreement between Peacock Engineering and Allergy Therapeutics includes vital support services, tested Disaster Recover, contractual Recovery Point and Return Time Objectives, and Patching. Other benefits of the upgrade include:
- Ongoing IT support
- Patching across IBM Websphere, including middleware, database platform and server operating systems
- Outstanding infrastructure support
- Improved efficiencies for engineering and maintenance teams
- Reduced existing hardware responsibilities
IBM Maximo is used by pharmaceutical, life science and manufacturing businesses around the world. As well as its robust regulation and compliance capabilities, the move to the cloud will enable Allergy Therapeutics to benefit from increased asset uptime, better first-time-fix rates, and improved overall operational efficiencies.
Lee Daley, Customer Success Executive at Peacock Engineering said:
“Allergy Therapeutics is a leader in its field, we are hugely proud to be supporting its team with its important work.
The new managed cloud-based service will ensure that the organisation meet the highest regulatory, compliance and safety standards, while also ensuring the UK and Spanish facilities are working to capacity.”